Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
Public ClinicalTrials.gov record NCT06280950. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (CTOT-43)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study from time of enrollment is 18-20 months.
Study identification
- NCT ID
- NCT06280950
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 340 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 11, 2024
- Primary completion
- Jun 29, 2028
- Completion
- Jun 29, 2030
- Last update posted
- Jul 23, 2026
2024 – 2030
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Hospital Arizona (Site #: 71144) | Phoenix | Arizona | 85054 | Recruiting |
| University of California, San Francisco (Site #: 71108) | San Francisco | California | 94143 | Recruiting |
| Northwestern University (Site #: 71110) | Chicago | Illinois | 60611 | Recruiting |
| Icahn School of Medicine at Mount Sinai (Site #: 71115) | New York | New York | 10029 | Recruiting |
| Duke University Medical Center (Site #: 71139) | Durham | North Carolina | 27710 | Recruiting |
| University of Pennsylvania (Site #: 71111) | Philadelphia | Pennsylvania | 19104 | Recruiting |
| University of Pittsburgh Medical Center (Site #: 71170) | Pittsburgh | Pennsylvania | 15260 | Recruiting |
| Baylor Medical Center (Site #: 71153) | Dallas | Texas | 75246 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06280950, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 23, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06280950 live on ClinicalTrials.gov.